ERP014106
Study Detail
| Title | Identification of ETO2-GLIS2 targets by ChIP-sequencing |
| Study Type | Whole Genome Sequencing |
| Abstract | Acute megakaryoblastic leukemia (AMKL) is a subtype of leukemia primarily diagnosed in childhood and generally associated with poor prognosis. Genetic alterations found in de novo childhood AMKL include the OTT-MAL fusion, MLL and NUP98 fusions and the recently identified ETO2-GLIS2 fusion that invo .. [more]lves two transcriptional regulators. In order to identify ETO2-GLIS2-bound regions as well as the chromatin landscape in human AMKL cells, we performed ChIP-seq analyses in AMKL MO7E cell line and in AMKL patient derived cells. Since existing GLIS2 antibodies could not successfully pull-down ETO2-GLIS2, we introduced the GFP at the endogenous GLIS2 loci in the MO7E cell line using a CRISPR/Cas9 approach to obtain physiological expression of a GFP-tagged ETO2-GLIS2 (MO7e-KI cell line). ChIP-seq were performed using antibody against GFP and ETO2 to identify ETO2-GLIS2-bound regions, against ERG to investigate colocalization and against chromatin marks to highlight repressed (H3K27me3) and active (H3K4me3: promoters; H3K27Ac, H3K4me1: enhancers) regions. [less] |
| Description | Acute megakaryoblastic leukemia (AMKL) is a subtype of leukemia primarily diagnosed in childhood and generally associated with poor prognosis. Genetic alterations found in de novo childhood AMKL include the OTT-MAL fusion, MLL and NUP98 fusions and the recently identified ETO2-GLIS2 fusion that invo .. [more]lves two transcriptional regulators. In order to identify ETO2-GLIS2-bound regions as well as the chromatin landscape in human AMKL cells, we performed ChIP-seq analyses in AMKL MO7E cell line and in AMKL patient derived cells. Since existing GLIS2 antibodies could not successfully pull-down ETO2-GLIS2, we introduced the GFP at the endogenous GLIS2 loci in the MO7E cell line using a CRISPR/Cas9 approach to obtain physiological expression of a GFP-tagged ETO2-GLIS2 (MO7e-KI cell line). ChIP-seq were performed using antibody against GFP and ETO2 to identify ETO2-GLIS2-bound regions, against ERG to investigate colocalization and against chromatin marks to highlight repressed (H3K27me3) and active (H3K4me3: promoters; H3K27Ac, H3K4me1: enhancers) regions. [less] |
| Center Name | INSERM U1170, Equipe Labellisee Ligue Contre le Cancer, Villejuif, France Institut Gustave Roussy, Villejuif, France Universite Paris Diderot, Paris, France |
SRA Links
| Url Link | E-MTAB-4367 in ArrayExpress |
Navigation
|
Submission | ERA560671 |
 FTP
|
|
| ERA775651 |
FTP
|
|||
|
Experiment | ERX1305842 |
FASTQ
|
SRA
|
| ERX1305843 |
FASTQ
|
SRA
|
||
| ERX1305844 |
FASTQ
|
SRA
|
||
| ERX1305845 |
FASTQ
|
SRA
|
||
| ERX1305846 |
FASTQ
|
SRA
|
||
| ERX1305847 |
FASTQ
|
SRA
|
||
| ERX1305848 |
FASTQ
|
SRA
|
||
| ERX1305849 |
FASTQ
|
SRA
|
||
| ERX1305850 |
FASTQ
|
SRA
|
||
| ERX1305851 |
FASTQ
|
SRA
|
||
| ERX1305852 |
FASTQ
|
SRA
|
||
| ERX1305853 |
FASTQ
|
SRA
|
||
| ERX1305854 |
FASTQ
|
SRA
|
||
| ERX1305855 |
FASTQ
|
SRA
|
||
| ERX1305856 |
FASTQ
|
SRA
|
||
| ERX1305857 |
FASTQ
|
SRA
|
||
| ERX1305858 |
FASTQ
|
SRA
|
||
| ERX1825292 |
FASTQ
|
SRA
|
||
| ERX1825293 |
FASTQ
|
SRA
|
||
| ERX1825294 |
FASTQ
|
SRA
|
||
| ERX1825295 |
FASTQ
|
SRA
|
||
| ERX1825296 |
FASTQ
|
SRA
|
||
| ERX1825297 |
FASTQ
|
SRA
|
||
| ERX1825298 |
FASTQ
|
SRA
|
||
| ERX1825299 |
FASTQ
|
SRA
|
||
| ERX1825300 |
FASTQ
|
SRA
|
||
| ERX1825301 |
FASTQ
|
SRA
|
||
|
|
Sample | ERS1049578 | ||
| ERS1049579 | ||||
| ERS1049580 | ||||
| ERS1049581 | ||||
| ERS1049582 | ||||
| ERS1049583 | ||||
| ERS1049584 | ||||
| ERS1049585 | ||||
| ERS1049586 | ||||
| ERS1049587 | ||||
| ERS1049588 | ||||
| ERS1049589 | ||||
| ERS1049590 | ||||
| ERS1049591 | ||||
| ERS1049592 | ||||
| ERS1049593 | ||||
| ERS1049594 | ||||
| ERS1473555 | ||||
| ERS1473556 | ||||
| ERS1473557 | ||||
| ERS1473558 | ||||
| ERS1473559 | ||||
| ERS1473560 | ||||
| ERS1473561 | ||||
| ERS1473562 | ||||
| ERS1473563 | ||||
| ERS1473564 |